Skip to main content
OpenTrials
Completed

NCT Number: NCT03609632

Understanding Hypoglycaemia After Bariatric Surgery

Postprandial hyperinsulinaemic hypoglycaemia is an increasingly recognized adverse side effect of bariatric surgery. Affected individuals experience low glucose levels 1-3 hours after intake of meals, accompanied by symptoms such as drowsiness, sweating, hunger and palpitations. Hypoglycaemia can be serious and have potential dangerous health impact (e.g. road accident or fall due to loss of consciousness). The pathophysiology is incompletely understood and more research is needed in search of preventive and therapeutic strategies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital

Bern, 3010, Switzerland

About this study

Obesity is a major global health concern that is associated with significant disability and mortality. Worldwide, the prevalence of obesity has doubled since 1980, affecting 13% of the global population. Bariatric surgery has been shown to be the most effective and durable treatment of severe obesity and leads to significant improvement of obesity-related comorbidity. However, postprandial hyperinsulinaemic hypoglycaemia (PHH) after bariatric surgery is a metabolic complication that is increasingly being recognized. Prevalence rates of up to 72% have been reported. PHH may have serious implications for affected patients, including negative effects on morbidity, mortality as well as quality of life. The pathophysiology of PPH is incompletely understood and suggests decreased adaptation of beta cell function to increased insulin sensitivity. The latter has been postulated to be largely secondary due to external factors outside the beta cells as a result of anatomical and hormonal changes after Roux-en-Y gastric bypass (RYGB). However, the intrinsic mechanistic effects of altered beta-cell function after RYGB in vivo are unknown and more exploration could lead to a better understanding of PHH pathogenesis and help identify targets for possible interventions. Previous studies performed enhanced beta cell analysis by following insulin synthesis in real-time based on stable isotope labelling of C-peptide during an oral glucose tolerance test (OGTT) in cohorts with normal and diabetic glucose tolerance. Applying the same methodological approach, albeit in a different target population (PPH after bariatric surgery), the present study seeks to explore whether or not the insulin hypersecretion can be explained by an increase in insulin synthesis, and secondly, whether potentially increased insulin synthesis can be related to other glucoregulatory hormones and measures of insulin sensitivity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gastric bypass (RYGB) surgery performed ≥ 6 months ago
  • Confirmed postprandial hypoglycaemia (continuous glucose monitoring or plasma glucose), with at least 2 episodes of Whipple's triad (symptoms, capillary of interstitial glucose ≤3.1mmol/L, symptom resolution by carbohydrate intake) ≤3 months ago
  • Normal glucose control at recruitment and absence of (pre)diabetes before bariatric surgery
  • Capacity to give informed consent

Exclusion criteria

  • Fasting hypoglycaemia suggesting hyperinsulinism of different aetiology
  • Use of medication that influence glucose metabolism
  • Bariatric procedures other than RYGB
  • Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Moderate to severe chronic kidney disease
  • Pregnancy or breastfeeding

Treatment and study plan

Dietary Supplement: Glucose

Other

Intake of 75g of glucose with 1g of 13C leucine pre-feeding

Primary outcomes

  1. Fractional synthesis rate of de novo C-peptide synthesis (%/hr)

    Time frame: 4.5 hours

    Calculated

Secondary outcomes

  1. C-peptide levels in blood

    Time frame: 4.5 hours

    Measured

  2. Insulin levels in blood

    Time frame: 4.5 hours

    Measured

  3. Glucagon levels in blood

    Time frame: 4.5 hours

    Measured

  4. Incretin levels in blood

    Time frame: 4.5 hours

    Measured

  5. Insulin sensitivity

    Time frame: 4.5 hours

    Calculated

  6. Beta cell responsivity

    Time frame: 4.5 hours

    Calculated

  7. Hepatic insulin extraction

    Time frame: 4.5 hours

    Calculated

  8. C-peptide levels in urine

    Time frame: 4.5 hours

    Measured

  9. C-peptide enrichment

    Time frame: 4.5 hours

    calculated

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Collaborators

  • Erasmus Medical Center

Registry information

Official study title

Exploring Beta Cell Function in Individuals With Postbariatric Postprandial

Acronym: HYPOBAR1

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 1, 2018
Registry last updated
Dec 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.